From the Guidelines
For a patient with pyelonephritis who has a Bactrim allergy and is taking QT-prolonging psychiatric medications, I recommend using ceftriaxone 1-2g IV daily for initial treatment, as suggested by the most recent guidelines 1. This approach is supported by the European Association of Urology guidelines on urological infections, which suggest using a long-acting parenteral antimicrobial, such as ceftriaxone, as an initial dose when fluoroquinolone resistance is a concern or the patient has a contraindication to fluoroquinolones, such as QT-prolonging medications 1. The choice of antibiotic should be guided by local antibiogram data, severity of infection, and patient-specific factors, including the presence of allergies and potential drug interactions 1. Some key points to consider in the treatment of pyelonephritis include:
- Obtaining urine cultures and susceptibility testing to confirm the causative organism and its susceptibilities 1
- Avoiding fluoroquinolones (ciprofloxacin, levofloxacin) due to their potential to prolong the QT interval and interact with psychiatric medications, potentially causing dangerous arrhythmias 1
- Considering alternative oral antibiotics, such as amoxicillin-clavulanate or cephalexin, for step-down therapy or for patients with mild to moderate infection and normal renal function 1
- Ensuring adequate hydration and fever control as important supportive measures 1
- Hospitalizing patients with severe infection and systemic symptoms for IV antibiotics until clinical improvement occurs, typically 24-48 hours, before transitioning to oral therapy 1
From the FDA Drug Label
5.9 Prolongation of the QT Interval Some fluoroquinolones, including levofloxacin, have been associated with prolongation of the QT interval on the electrocardiogram and infrequent cases of arrhythmia. Rare cases of torsade de pointes have been spontaneously reported during postmarketing surveillance in patients receiving fluoroquinolones, including levofloxacin Levofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents.
Treatment of Pyelonephritis with Levofloxacin in a Patient with Allergy to Bactrim and Taking Psych QT Prolonging Medications: Levofloxacin can be used to treat pyelonephritis, but it should be used with caution in patients taking psych QT prolonging medications due to the risk of prolongation of the QT interval.
- The patient's QT interval should be monitored closely.
- The patient should be advised to report any symptoms of prolongation of the QT interval, such as prolonged heart palpitations or loss of consciousness.
- Alternative treatments should be considered if possible.
- The patient's renal function should also be monitored, as levofloxacin is substantially excreted by the kidney. 2
From the Research
Treatment Options for Pyelonephritis
- For patients with an allergy to Bactrim (trimethoprim/sulfamethoxazole), alternative antibiotics such as fluoroquinolones (e.g., ciprofloxacin, levofloxacin) or oral cephalosporins can be considered 3, 4.
- When local resistance to a chosen oral antibiotic likely exceeds 10%, one dose of a long-acting broad-spectrum parenteral antibiotic should also be given while awaiting susceptibility data 3.
Considerations for Patients Taking Psych QT Prolonging Medications
- Fluoroquinolones, such as ciprofloxacin and levofloxacin, can also prolong the QT interval, which may increase the risk of cardiac arrhythmias when combined with psych QT prolonging medications 5, 6.
- Oral cephalosporins may be a safer alternative in this case, as they are less likely to interact with psych QT prolonging medications 4.
Duration of Antibiotic Therapy
- Short-course antibiotic treatment (7-10 days) may be as effective as longer courses (14 days) for the treatment of acute uncomplicated pyelonephritis 7, 5, 6.
- The choice of antibiotic and duration of therapy should be guided by urine culture and susceptibility results, as well as the patient's clinical response to treatment 3, 7.